Carmiel, Israel – September 11, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) confirmed that Chief Financial Officer Gilad Mamlok will represent the company at two investor conferences in New York City this month.
Mamlok addresses H.C. Wainwright's 28th Annual Global Investment Conference on September 14
The presentation is scheduled for 2:00 p.m. EDT during the three-day event running September 14-16, 2026.
Morgan Stanley's 24th Annual Global Healthcare Conference hosts a fireside chat on September 16
The session is set for 1:05 p.m. EDT and will be streamed via a live audio webcast, with an archived replay available afterward on Protalix's investor relations site.
Protalix markets two enzyme replacement therapies through partnerships with Chiesi and Pfizer
Elfabrio, approved for Fabry disease in the U.S. and EU, is commercialized with Chiesi Global Rare Diseases, while Elelyso for Gaucher disease is sold in 23 markets through a partnership with Pfizer Inc., excluding Brazil where Fundação Oswaldo Cruz holds distribution rights. Both therapies are produced using Protalix's proprietary ProCellEx plant cell-based expression platform.
Pipeline includes a Phase 2 gout treatment and a DNase I candidate for NETs-related diseases
Protalix's development programs include PRX-115, a PEGylated uricase for uncontrolled gout currently in the Phase 2 RELEASE trial, and PRX-119, a long-acting DNase I therapy targeting neutrophil extracellular trap-related diseases.